Trial reportBreast cancer (Tokyo, Japan)2026
Minimal important differences of EORTC QLQ-C30 and QLQ-BR23 for metastatic breast cancer patients in a Japanese population: results from the RESQ trial.
Trial report in Breast cancer (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundEuropean Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and breast cancer–specific quality-of-life questionnaire (QLQ-BR23) are widely used in clinical trials, but information on minimal important differences (MIDs) remain limited.
methodsData were obtained from the RESQ trial, a phase 3 study conducted in Japan. A total of 302 patients with HER2-negative metastatic breast cancer were randomized to receive eribulin or S-1. QLQ-C30 and QLQ-BR23 were administered every six weeks until week 24 and every nine weeks until week 42. The trial’s preplanned secondary analysis aimed to estimate group-level MIDs for both questionnaires. Subjective significance questionnaire and performance status (PS) served as anchors to estimate MIDs.
resultsOf the 302 patients, 270 were included in this analysis. The median age was 61 years. At baseline, 73.0% had a PS of 0, and 27.0% had a PS of 1 or 2. Within-group MIDs were estimated for 11 domains of the QLQ-C30 and 5 domains of the QLQ-BR23, ranging from 6 to 14 points for improvement and − 5 to − 17 points for deterioration. Between-group MIDs were estimated for 7 domains of the QLQ-C30, ranging from 4 to 7 points for improvement and − 4 to − 9 points for deterioration; none were estimated for the QLQ-BR23.
conclusionsThis study provides the first MID estimates for the QLQ-BR23 and expands MID for the QLQ-C30 in patients with metastatic breast cancer. These findings offer benchmarks for interpreting quality-of-life outcomes and support the clinical relevance of patient-reported measures.[ 250 / 250 ].
Indexed as
Identifiers
41910921What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.